2,4,6-三溴吡啶 | 2408-70-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,4,6-三溴吡啶
• 英文名称: 2,4,6-tribromopyridine
• 英文别名: 2,4,6-Tribrompyridin
• CAS: 2408-70-0
• 化学式: C₅H₂Br₃N
• 分子量: 315.79
• InChiKey: WALXYTCBNHJWER-UHFFFAOYSA-N

物化性质

• 熔点：
  105-106℃
• 沸点：
  306℃
• 密度：
  2.406
• 闪点：
  139℃
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,4,6-Tribromopyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,4,6-Tribromopyridine
CAS number: 2408-70-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H2Br3N
Molecular weight: 315.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4,6-三溴吡啶 在 氨 、 正丁醇 作用下， 生成 2-氨基-4,6-二溴吡啶
  参考文献：
  名称：

  den Hertog, Recueil des Travaux Chimiques des Pays-Bas, 1946, vol. 65, p. 129,136

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Amino-2,4,6-tribromopyridine 在 硫酸 、 溶剂黄146 作用下， 生成 2,4,6-三溴吡啶
  参考文献：
  名称：

  Plazek; Marcinkow, Roczniki Chemii, 1934, vol. 14, p. 326,330

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS COMME INHIBITEURS DE PROTÉINES KINASES
  申请人：NOVARTIS AG

  公开号：WO2016038582A1

  公开（公告）日：2016-03-17

  The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

  本发明提供了如下所述的化合物(I)和(II)，以及其盐，并且提供了这些化合物用于治疗与Raf激酶活性相关的疾病的治疗用途。该发明还提供了包含这些化合物的药物组合物，以及包含这些化合物和治疗协同剂的组合物。
• Mono- and multifold C–C coupling reactions catalyzed by a palladium complex encapsulated in MIL-Cr as a three dimensional nano reactor
  作者：Saghar Rezaei、Amir Landarani-Isfahani、Majid Moghadam、Shahram Tangestaninejad、Valiollah Mirkhani、Iraj Mohammadpoor-Baltork

  DOI：10.1039/c6ra11212a

  日期：——

  The organic palladium complex (trans-dichlorobis(4-iodoaniline-κN)palladium(II)) was encapsulated into a porous metal–organic framework MIL-Cr (Pd complex@MIL-Cr) using ship-in-a-bottle strategy. The novel catalyst as a three dimensional nanoreactor was fully characterized using different techniques such as XRD, BET, XPS, SEM, EDX, TEM and ICP. The Pd complex@MIL-Cr is isostructural to the parent MIL-Cr

  有机钯配合物（反式-二氯双（4-碘苯胺-κN）钯（II））通过瓶装策略封装在多孔的金属有机框架MIL-Cr（Pd complex @ MIL-Cr）中。使用不同的技术，如XRD，BET，XPS，SEM，EDX，TEM和ICP，对新型作为三维纳米反应器的催化剂进行了全面表征。Pd complex @ MIL-Cr与母体MIL-Cr骨架是同构的，具有约200的高表面积和孔体积。1418 m 2 g -1和0.87 cm 3 g -1， 分别。纳米反应器在芳基卤化物的催化转化中非常高效，显示出比均相Pd对应物更高的活性。出乎意料的是，在具有广泛取代基的氯代芳烃的Suzuki-Miyaura和Heck偶联反应中实现了高收率。此外，该方案可以扩展到2-溴和2,6-二溴吡啶与芳基硼酸的交叉偶联，在室温下具有优异的收率。Pd配合物@ MIL-Cr还用作制备一系列C 3的高效便捷催化剂以苯，吡啶或嘧啶单元
• Cercosporin-bioinspired photoreductive activation of aryl halides under mild conditions
  作者：Zhaocheng Tang、Jia Li、Fulin Lin、Wenhao Bao、Shiwei Zhang、Baodang Guo、Shuping Huang、Yan Zhang、Yijian Rao

  DOI：10.1016/j.jcat.2019.09.036

  日期：2019.12

  here we took advantage of the photophysical properties of cercosporin, and used it as a metal-free photocatalyst to develop an unprecedented cercosporin-driven photocatalysis under mild conditions. Furthermore, the forming conditions and excited-state dynamics of radical anions of cercosporin have been systematically investigated. In particular, transient femtosecond absorption spectroscopy was employed

  由自然产生的头孢菌素驱动的植物病原真菌Cercospora sp。感染过程的生物启发在这里，我们利用了头孢菌素的光物理性质，并将其用作不含金属的光催化剂，在温和条件下开发了前所未有的头孢菌素驱动的光催化。此外，对头孢菌素自由基阴离子的形成条件和激发态动力学进行了系统的研究。特别是，采用瞬时飞秒吸收光谱法揭示了头孢菌素的激发态动力学，这是决定其在光催化作用中的关键步骤。我们表明，尾孢菌素能够通过两步激发而被充分激活，从而最终提高了其光催化活性，从而以极低的反应性还原了底物。
• Novel compounds, their preparation and use
  申请人：Havranek Miroslav

  公开号：US20090209588A1

  公开（公告）日：2009-08-20

  Novel compounds of the general formula (I), in which the variables are as defined in claim 1 , the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.

  通用公式(I)的新化合物，其中变量的定义如权利要求1中所述，这些化合物作为药物组成物的用途，包含这些化合物的药物组成物以及使用这些化合物和组成物进行治疗的方法。这些化合物在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型，即1型糖尿病、2型糖尿病、血脂异常、X综合征（包括代谢综合征，即糖耐量受损、胰岛素抵抗、高三酰甘油血症和/或肥胖）、心血管疾病（包括动脉粥样硬化）和高胆固醇血症。
• [EN] NOVEL COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] NOUVEAUX COMPOSES, LEUR PREPARATION ET LEUR UTILISATION
  申请人：NOVO NORDISK AS

  公开号：WO2005105726A1

  公开（公告）日：2005-11-10

  Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.

  通用公式（I）的新化合物，其中变量如权利要求书中所定义的，这些化合物的用途作为药物组合物，包含这些化合物的药物组合物以及使用这些化合物和组合物进行治疗的方法。这些化合物在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，特别是PPARδ亚型，即1型糖尿病、2型糖尿病、血脂异常、X综合症（包括代谢综合症，即糖耐量受损、胰岛素抵抗、高三酸甘油酯血症和/或肥胖）、心血管疾病（包括动脉粥样硬化）和高胆固醇血症的治疗中有用。